Sihuan Pharma FY26 H1 profit attributable to owners rises 119% to RMB 224.7 million; revenue increases 1.3% to RMB 1.16 billion

• Sihuan Pharmaceutical posted profit attributable to owners of RMB 224.7 million, more than doubled year on year; basic EPS was RMB 2.49 cents.
• Revenue rose 1.3% to RMB 1.16 billion, with medical aesthetics up 18.5% to RMB 693.3 million.
• Profit before tax climbed 133.3% to RMB 366 million, helped by a RMB 154.2 million gain on disposal of a subsidiary.
• Gross profit fell 10% to RMB 681.7 million; gross margin dropped 7.4 percentage points to 58.7% on generic drug price adjustments.
• Cash and equivalents, wealth management products, pledged deposits, and time deposits totaled RMB 4.02 billion at June 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299531), on August 26, 2026, and is solely responsible for the information contained therein.